Ensuring Access to Lower-Cost Medicines for Seniors Act

The Ensuring Access to Lower-Cost Medicines for Seniors Act (S.4323) was introduced in the Senate on April 16, 2026, and referred to the Committee on Finance. It requires Medicare Part D prescription drug plans that use formularies to include generic drugs and biosimilars on those formularies, and to place them on cost-sharing tiers no less favorable than brand-name drugs, without more restrictive utilization management requirements. This is a regulatory mandate, not an appropriation—no direct federal spending is authorized. The mechanism forces plans to guarantee access to lower-cost alternatives, which structurally benefits manufacturers of generics and biosimilars by increasing their market access and volume. Conversely, it limits the ability of PBMs and insurers to use formulary restrictions to steer patients toward higher-margin brand drugs, potentially reducing rebate revenue. The bill is early-stage; it must pass committee, both chambers, and be signed into law. If enacted, the provisions apply to plan years beginning on or after January 1, 2028. The primary winners are pure-play generic and biosimilar companies; losers are brand-name drug manufacturers with high-priced Part D drugs and PBMs that rely on brand drug rebates. No convergence signals were provided. The legislative path is uncertain, but the bill has bipartisan cosponsors (Lankford-R, Hassan-D, Bennet-D), indicating some momentum.